Fortovase (saquinavir)
- Region
- 🇪🇺 EU
- Active substance
- saquinavir
- Company
- Roche Registration Ltd.
- Status
- Withdrawn
- Therapeutic area
- HIV Infections
- EU approval
- Thu 20 Aug 1998
- Application
- EMEA/H/C/000178
- ATC
- J05AE01
- Official record
- www.ema.europa.eu
Indication
Fortovase is indicated for treatment of HIV-1 infected adult patients. Fortovase should only be given in combination with ritonavir and other antiretroviral medicinal products (see section 4.2).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Invirase Withdrawn · Roche Registration GmbH
Follow Fortovase
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.